Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press86410.17650/2313-805X-2026-13-3-68-79REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИReview ArticleThe role of the plasminogen activator inhibitor type 1 in oncogenesisРоль ингибитора активатора плазминогена 1-го типа в онкогенезеhttps://orcid.org/0000-0001-8501-7917KorolyovaAnna A.КоролёваАнна Анатольевна
Russian Federation

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

Научно-исследовательский институт урологии и интервенционной радиологии им. Н. А. Лопаткина

anna.korolyova@hotmail.comhttps://orcid.org/0009-0004-4720-3240KibalinaD. I.КибалинаД. И.
Russian Federation
anna.korolyova@hotmail.comGroup of Companies “Medsi”АО «Группа компаний «Медси»National Medical Research Radiology Centre, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииVladimir branch of the Privolzhsky Research Medical University, Ministry of Health of RussiaВладимирский филиал ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииNovosibirsk State Medical University, Ministry of Health of RussiaФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава Россииru22092026202613368791905202622092026Received:19052026Accepted:22092026Published:22092026Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://umo.abvpress.ru/jour/about/editorialPolicieshttps://umo.abvpress.ru/jour/article/view/864

Plasminogen activator inhibitor type 1 (PAI-1) (serine protease inhibitor SERPINE1) belongs to the serine protease inhibitor superfamily and is found in many cell types, including megakaryocytes, platelets, adipocytes, endothelial cells, hepatocytes and smooth muscle cells. It is primarily studied as a regulator of the fibrinolytic system. In recent years, various functions of this protein have been discovered, and it is now considered an important component of many pathological processes and diseases, such as metabolic syndrome, chronic kidney disease, neuropsychiatric disorders and others. This serpin is one of the factors that determine the clinical course of infectious diseases. In the literature there is a justified statement about this protein: “serpin with a finger in many PAIs”. These findings suggest that PAI-1 may be a promising target for the treatment of various diseases. In addition, the role of this protein in oncogenesis has been studied for 40 years. The article provides an overview of current data on the role of PAI-1 in oncogenesis, the potentiation of chemotherapy and radiotherapy resistance of tumor cells, and the first experience in creating PAI-1 inhibitors in clinical oncology.

Ингибитор активатора плазминогена 1-го типа (PAI-1) (ингибитор сериновой протеиназы SERPINE1) относится к суперсемейству ингибиторов сериновых протеаз. Он обнаружен во многих типах клеток, в том числе в мегакариоцитах, тромбоцитах, адипоцитах, эндотелиальных клетках, гепатоцитах, гладкомышечных клетках и изучен прежде всего как регулятор фибринолитической системы. В последние годы стали известны различные функции этого белка, и в настоящее время он считается важной составляющей многих патологических процессов и заболеваний: метаболического синдрома, хронической болезни почек, нервно-психических заболеваний и др. Данный серпин является одним из факторов, определяющих клиническое течение инфекционных заболеваний. В литературе встречается такая характеристика этого белка: «серпин, указывающий на множество проблем». Имеющиеся данные подтверждают, что PAI-1 может стать перспективной мишенью для лечения различных заболеваний. Помимо этого, в течение 40 лет изучается его роль в развитии онкологических заболеваний.

В статье представлен обзор литературы, посвященной роли PAI-1 в развитии рака, потенцировании химио- и радиорезистентности опухолевых клеток, а также описан первый опыт создания ингибиторов PAI-1 в клинической онкологии.

inhibitor of plasminogen activator type 1PAI-1serine protease inhibitor SERPINE1oncogenesisингибитор активатора плазминогена 1PAI-1ингибитор сериновой протеиназы SERPINE1онкогенезYu Y., Li W., Xu L., Wang Y. Circadian rhythm of plasminogen activator inhibitor-1 and cardiovascular complications in type 2 diabetes. Front Endocrinol 20203;14:1124353. DOI: 10.3389/fendo.2023.1124353Tipoe T.L., Wu W.K.K., Chung L. et al. Plasminogen activator inhibitor 1 for predicting sepsis severity and mortality outcomes: a systematic review and meta-analysis. Front Immunol 2018;9:1218. DOI: 10.3389/fimmu.2018.01218Kaji H. Adipose tissue-derived plasminogen activator inhibitor-1 function and regulation. Compr Physiol 2016;6(4):1873–96. DOI: 10.1002/cphy.c160004Lentz S.R. Thrombosis in the setting of obesity or inflammatory bowel disease. Hematology Am Soc Hematol Educ Program 2016;2016(1):180–7. DOI: 10.1182/asheducation-2016.1.180Morrow G.B., Whyte C.S., Mutch N.J. A serpin with a finger in many PAIs: PAI-1’s central function in thromboinflammation and cardiovascular disease. Front Cardiovasc Med 2021;8:653655. DOI: 10.3389/fcvm.2021.653655Liu Y., Cheng J., Guo X. et al. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects. Gene 2018;673: 167–73. DOI: 10.1016/j.gene.2018.06.040Zahran M., Nasr F.M., Metwaly A.A. et al. The role of hemostatic factors in atherosclerosis in patients with chronic renal disease. Electron Physician 2015;7(5):1270–6. DOI: 10.14661/1270Tang J., Zhu W., Mei X., Zhang Z. Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty. J Orthop Surg Res 2018;13(1):8. DOI: 10.1186/s13018-018-0716-2Wang L., Chen L., Liu Z. et al. PAI-1 exacerbates white adipose tissue dysfunction and metabolicdysregulation in high fat diet-induced obesity. Front Pharmacol 2018;9:1087. DOI: 10.3389/fphar.2018.01087Nougier C., Benoit R., Simon M. et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020;18(9):2215–9. DOI: 10.1111/jth.15016Zuo Y., Warnock M., Harbaugh A. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021;11(1):1580. DOI: 10.1038/s41598-020-80010-zKang S., Tanaka T., Inoue H. et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascularendothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA 2020;117(36):22351–6. DOI: 10.1073/pnas.2010229117Rossi B., Nguyen L.S., Zimmermann P. et al. Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case-control cohort study. Pharmaceuticals (Basel) 2020;13(10):317. DOI: 10.3390/ph13100317Whyte C.S., Simpson M., Morrow G.B. et al. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. J Thromb Haemost 2022;20(10):2394–406. DOI: 10.1111/jth.15806Cohen C., Le Goff O., Soysouvanh F. et al. Glomerular endothelial cell senescence drives age-related kidney disease through PAI-1. EMBO Mol Med 2021;13(11):e14146. DOI: 10.15252/emmm.202114146Ågren M.S., Litman T., Eriksen J.O. et al. Gene expression linked to reepithelialization of human skin wounds. Int J Mol Sci 2022;23(24):15746. DOI: 10.3390/ijms232415746Simone T.M., Higgins P.J. Inhibition of SERPINE1 function attenuates wound closure in response to tissue injury: a role for PAI-1 in re-epithelialization and granulation tissue formation. J Dev Biol 2015;3:11–24. DOI: 10.3390/jdb3010011Khan S.S., Shah S.J., Klyachko E. et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci Adv 2017;3(11):eaao1617. DOI: 10.1126/sciadv.aao1617Yang C.-W., Chen C.-L., Chou W.-C. et al. An Integrative Transcriptomic Analysis for Identifying Novel Target Genes Corresponding to Severity Spectrum in Spinal Muscular Atrophy. PLoS One 2016;11(6):e0157426. DOI: 10.1371/journal.pone.0157426Bahi A., Steele S. Novel roles for urokinase- and tissue-type plasminogen activators in the pathogenesis of mood disorders. Int J Mol Sci 2025;26(14):6899. DOI: 10.3390/ijms26146899Wang Y., Wang J., Gao J. et al. The expression of SERPINE1 in colon cancer and its regulatory network and prognostic value. BMC Gastroenterol 2023;23(1):33. DOI: 10.1186/s12876-022-02625-yFalanga A., Santoro A., Labianca R. et al. HYPERCAN Study Group. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thromb Res 2016;140(1):S55–9. DOI: 10.1016/S0049-3848(16)30099-8Oh J., An H.J., Kim J.O. et al. Association between five common plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms and colorectal cancer susceptibility. Int J Mol Sci 2020;21(12):4334. DOI: 10.3390/ijms21124334Wang J., Peng Y., Guo H., Li C. PAI-1 polymorphisms have significant associations with cancer risk, especially feminine cancer. Technol Cancer Res Treat 2021;20:1–16. DOI: 10.1177/15330338211037813Subbiah U., Sivakumar K. Genetic association of plasminogen activator inhibitor-1 gene polymorphisms (rs2227631 and rs6092) with susceptibility to oral premalignant disorders in a South Indian cohort. Oral Maxillofac Surg 2025;29(1):52. DOI: 10.1007/s10006-025-01350-6Paul E.N., Burns G.W., Carpenter T.J. et al. Transcriptome analyses of myometrium from fibroid patients reveals phenotypic differences compared to non-diseased myometrium. Int J Mol Sci 2021;22(7):3618. DOI: 10.3390/ijms22073618Bharadwaj A.G., Holloway R.W., Miller V.A., Waisman D.M. Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers 2021;13(8):1838. DOI: 10.3390/ cancers13081838Hisada Y., Garratt K.B., Maqsood A. et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Adv 2021;5(2):487–95. DOI: 10.1182/bloodadvances.2020003149Wang H.C., Lin Y.L., Hsu C.C. et al. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Theranostics 2019;9(24):7168–83. DOI: 10.7150/thno.36830Park J., Wysocki R.W., Amoozgar Z. et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 2016;8:361:361ra138. DOI: 10.1126/scitranslmed.aag1711Noubouossie D.F., Reeves B.N., Strahl B.D., Key N.S. Neutrophils: back in the thrombosis spotlight. Blood 2019;l133(20):2186–97. DOI: 10.1182/blood-2018-10-862243Peng Y., Kajiyama H., Yuan H. et al. PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett 2019;442:181–92. DOI: 10.1016/j.canlet.2018.10.027Polo-Generelo S., Rodríguez-Mateo C., Torres B. et al. Serpine1 mRNA confers mesenchymal characteristics to the cell and promotes CD8+ T cells exclusion from colon adenocarcinomas. Cell Death Discov 2024;10(1):116. DOI: 10.1038/s41420-024-01886-8Muñoz-Galván S., Rivero M., Peinado-Serrano J. et al. PAI1 is a marker of bad prognosis in rectal cancer but predicts a better response to treatment with PIM inhibitor AZD1208. Cells 2020;9(5):1071. DOI: 10.3390/cells9051071Wang D., Yang L.Y., Liu Z. et al. PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells. Yi Chuan 2020;20;42(3):287–95. DOI: 10.16288/j.yczz.19-334Sakamoto H., Koma Y.I., Higashino N. et al. PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages. Lab Invest 2021;101(3):353–68. DOI: 10.1038/s41374-020-00512-2Teng F., Zhang J.X., Chen Y. et al. LncRNA NKX2‐1‐AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR‐2 signaling pathway in gastric cancer. Mol Oncol 2021;15(4):1234–55. DOI: 10.1002/1878-0261.12911Chen S., Li Y., Zhu Y. et al. SERPINE1 overexpression promotes malignant progression and poor prognosis of gastric cancer. J Oncol 2022;2022:2647825. DOI: 10.1155/2022/2647825Yang J.-D., Ma L., Zhu Z. SERPINE1 as a cancer-promoting gene in gastric adenocarcinoma: facilitates tumour cell proliferation, migration, and invasion by regulating EMT. J Chemother 2019;31(7–8):408–18. DOI: 10.1080/1120009X.2019.1687996Xu B., Bai Z., Yin J, Zhang Z. Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer. Peer J 2019;7:e7091. DOI: 10.7717/peerj.7091Pastorino G.A., Sheraj I., Huebner K. et al. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction. J Pathol 2024;262(3):347–61. DOI: 10.1002/path.6240Wang S., Pang L., Liu Z., Meng X. SERPINE1 associated with remodeling of the tumor microenvironment in colon cancer progression: a novel therapeutic target. BMC Cancer 2021;21(1):767. DOI: 10.1186/s12885-021-08536-7Pranteda A., Piastra V., Stramucci L. et al. The p38 MAPK signaling activation in colorectal cancer upon therapeutic treatments. Int J Mol Sci 2020;21(8):2773. DOI: 10.3390/ijms21082773Guo X., Sun Z., Chen H. et al. SERPINE1 as an independent prognostic marker and therapeutic target for nicotine-related oral carcinoma. Clin Exp Otorhinolaryngol 2022;16(1):75–86. DOI: 10.21053/ceo.2022.01480Thakore V.P., Patel K.D., Bhadresha K.P. et al. An integrative analysis to enumerate candidate genes for clinical use in oral cancer. J Cancer Res Ther 2022;18(Supplement):S182–90. DOI: 10.4103/jcrt.JCRT_1607_20Pavón M.A., Arroyo-Solera I., Téllez-Gabriel M. et al. Enhanced cell migration and apoptosis resistancemay underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget 2015;6(30):29016–33. DOI: 10.18632/oncotarget.5032Zhou Q., Yuan O., Cui H. et al. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma. Front Cell Infect Microbiol 2022;12:1007950. DOI: 10.3389/fcimb.2022.1007950Chen G., Sun J., Xie M. et al. PLAU promotes cell proliferation and epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Front Genet 2021;12:651882. DOI: 10.3389/fgene.2021.651882Kisoda S., Shao W., Fujiwara N. et al. Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis. Oral Dis 2020;26(6):1149–56. DOI: 10.1111/odi.13351Ge Y., Li W., Ni Q. et al. Weighted gene co-expression network analysis identifies hub genes associated with occurrence and prognosis of oral squamous cell carcinoma. Med Sci Monit 2019;25:7272–88. DOI: 10.12659/MSM.916025Huang J., Meng Q., Liu R. et al. The development of radioresistant oral squamous carcinoma cell lines and identification of radiotherapy-related biomarkers. Clin Transl Oncol 2023;25(10):3006–20. DOI: 10.1007/s12094-023-03169-7Xie P., Wu S., Guo L. et al. Identification of candidate target genes and immune cells in oral squamous cell carcinoma. Comput Math Methods Med 2021;2021:5802110. DOI: 10.1155/2021/5802110Jamshidi S., Tavangar M., Shojaei S., Taherkhani A. Malignant transformation of normal oral tissue to dysplasia and early oral squamous cell carcinoma: an in silico transcriptomics approach. Anal Cell Pathol (Amst) 2024;2024:6260651. DOI: 10.1155/2024/6260651Feng S., Wang Z., Zhang H. et al. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy. J Gene Med 2024;26(1):e3643. DOI: 10.1002/jgm.3643Shao H., Li X., Wu P. et al. A cellular senescence-related signature predicts cervical cancer patient outcome and immunotherapy sensitivity. Reprod Sci 2023;30(12):3661–76. DOI: 10.1007/s43032-023-01305-wZhang Y., Zhu J., Hu K. et al. Multi-omics analyses construct an inflammatory response based prognostic gene signature for cervical cancer and suggest tumor infiltrating monocytes subgroups as key players. Front Immunol 2025;16:1563593. DOI: 10.3389/fimmu.2025.1563593Lyu X., Li G., Qiao Q. Identification of an immune classification for cervical cancer and integrative analysis of multiomics data. J Transl Med 2021;19(1):200. DOI: 10.1186/s12967-021-02845-yHuang X., Wang L., Guo H. et al. Single-cell RNA sequencing reveals SERPINE1-expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma. Clin Transl Med 2024;14(1):e1527. DOI: 10.1002/ctm2.1527Moeini P., Niedzwiedzka-Rystwej P. Tumor-associated macrophages: Combination of therapies, the approach to improve cancer treatment. Int J Mol Sci 2021;22(13):7239. DOI: 10.3390/ijms22137239Wang S., Wang J., Chen Z. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 2024;8(1):31. DOI: 10.1038/s41698-024-00522-zChen S., Morine Y., Tokuda K. et al. Cancer-associated fibroblast-induced M2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway. Int J Oncol 2021;59(2):59. DOI: 10.3892/ijo.2021.5239Nagy A., Munkacsy G., Gyorffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep 2021;11(1):6047. DOI: 10.1038/s41598-021-84787-5Zhang W., Yang S., Chen D. et al. SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling. Cell Mol Life Sci 2022;79(1):59. DOI: 10.1007/s00018-021-04120-1Wieder V., Engel J., Eichstädt K. et al. Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer. Breast Cancer Res Treat 2025;215(1):31. DOI: 10.1007/s10549-025-07850-zChandrashekar D.S., Bashel B., Balasubramanya S.A.H. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19(8):649–58. DOI: 10.1016/j.neo.2017.05.002Brett E., Sauter M., Timmins É. et al. Oncogenic linear collagen VI of invasive breast cancer is induced by CCL5. J Clin Med 2020;9(4):991. DOI: 10.3390/jcm9040991Han W., Chen S., Yuan W. et al. Oriented collagen fibers direct tumor cell intravasation. Proc Natl Acad Sci USA 2016;113(40):11208–13.Humphries B.A., Buschhaus J.M., Chen Y.C. et al. Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol Cancer Res 2019;17(5):1142–54. DOI: 10.1158/1541-7786.MCR-18-0836Rangel R., Lee S.C., Hon-KimBan K. et al. Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proc Natl Acad Sci USA 2016;113:E7749–58. DOI: 10.1073/pnas.1613859113Pavlova N.N., Thompson C.B. The emerging hallmarks of cancer metabolism. Cell Metab 2016;23:27–47. DOI: 10.1016/j.cmet.2015.12.006Shiraishi T., Verdone J.E., Huang J. et al. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget 2015;6: 130–43. DOI: 10.18632/oncotarget.2766Wei X., Li S., He J. et al. Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling. Cell Commun Signal 2019;17(1):58. DOI: 10.1186/s12964-019-0373-zZhang W., Xu J., Fang H. et al. Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling FASEB J 2018;32(1):276–88. DOI: 10.1096/fj.201700237rrChe Y., Wang J., Li Y. et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death Dis 2018;9(7):759. DOI: 10.1038/s41419-018-0808-2Su Y.H., Wu Y.Z., Ann D.K. et al. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer. Cell Death Dis 2023;14(1):53. DOI: 10.1038/s41419-023-05576-8Zhang Q., Lei L., Jing D. Knockdown of SERPINE1 reverses resistance of triplenegative breast cancer to paclitaxel via suppression of VEGFA. Oncol Rep 2020;44(5):1875–84. DOI: 10.3892/or.2020.7770Zhang Q., Liu B., Lei L. et al. [SERPINE1 overexpression promotes proliferation and paclitaxel resistance of triple-negative breast cancer cells by inducing M2 macrophage polarization]. Nan Fang Yi Ke Da Xue Xue Bao 2025;45(12):2551–60. (In Chinese). DOI: 10.12122/j.issn.1673-4254.2025.12.03Hongu T., Sarenqiqige, Shandan et al. Permeable lung vasculature creates chemoresistant endothelial niche by producing SERPINE1 at breast cancer metastatic sites. Cancer Sci 2025;116(6):1604–15. DOI: 10.1111/cas.70050Tokumo K., Masuda T., Nakashima T. et al. Association between plasminogen activator inhibitor-1 and osimertinib tolerance in EGFR-mutated lung cancer via epithelial-mesenchymal transition. Cancers 2023;15(4):1092. DOI: 10.3390/cancers15041092Thu Y.M., Suzawa K., Tomida S. et al. PAI-1mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer. PLoS One 2024;19(5):e0300644. DOI: 10.1371/journal.pone.0300644Pan J.X., Qu F., Wang F.F. et al. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. Arch Gynecol Obstet 2017;296(6):1145–52. DOI: 10.1007/s00404-017-4547-xYagi T., Sawada K., Miyamoto M. et al. Continuous administration of anti-VEGFA antibody upregulates PAI-1 secretion from ovarian cancer cells via miR-143-3p Downregulation. Mol Cancer Res 2023;21(10):1093–106. DOI: 10.1158/1541-7786.MCR-23-0015Tzeng H.T., Yang J.L., Tseng Y.J. et al. Plasminogen activator inhibitor-1 secretion by autophagy contributes to melanoma resistance to chemotherapy through tumor microenvironment modulation. Cancers (Basel) 2021;13(6):1253. DOI: 10.3390/cancers13061253Ibrahim A.A., Fujimura T., Uno T. et al. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1. Front Immunol 2024;15:1365894. DOI: 10.3389/fimmu.2024.1365894Lin X., Kang K., Chen P. et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer 2024;23(1):108. DOI: 10.1186/s12943-024-02023-wTseng Y.-J., Lee C.-H., Chen W.-Y. et al. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade. J Invest Dermatol 2021;141(11):2690–2698.e6. DOI: 10.1016/j.jid.2021.03.030Zhang Y.P., Guo Z.Q., Cai X.T. et al. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell 2025;43(5):856–74.e9. DOI: 10.1016/j.ccell.2025.02.024Placencio V.R., Ichimura A., Miyata T., DeClerck Y.A. Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity. PLoS One 2015;10(7):e0133786. DOI: 10.1371/journal.pone.0133786Mashiko S., Kitatani K., Toyoshima M. et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther 2015;16(2):253–60. DOI: 10.1080/15384047.2014.1001271Miyata T. Overview: PAI-1 inhibitors and clinical applications. Biomed J 2025;49(1):100874. DOI: 10.1016/j.bj.2025.100874Hirai T., Asano K., Ito I. et al. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Sci Rep 2024;14(1):165. DOI: 10.1038/s41598-023-50445-1Takahashi N., Kameoka Y., Onizuka M. et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Med 2023;12(4):4250–8. DOI: 10.1002/cam4.5292Fujimura T., Asano Y. PAI-1 in skin malignancies: a central regulator of tumor progression and therapeutic resistance. Curr Treat Options Oncol 2025;26(11):943–9. DOI: 10.1007/s11864-025-01357-xFujihara H., Aoki G., Akita T. et al. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer. J Thorac Dis 2024;16(5):3381–8. DOI: 10.21037/jtd-23-1858Anniwaer G., Tsuji K., Sato S. et al. PAI-1 inhibitor TM5614 leads osteosarcoma cells to G2 arrest. J Med Dent Sci 2023;70:23–32. DOI: 10.11480/jmds.700003Fujimura T., Yoshino K., Nakamura M. et al. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: phase II study protocol. Exp Dermatol 2024;33(1):e1497. DOI: 10.1111/exd.14976Feng L., Li G., Li D. et al. Cuproptosis-related gene SERPINE1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. J Cancer Res Clin Oncol 2023;149(12):10851–65. DOI: 10.1007/s00432-023-04900-1Nakatsuka E., Sawada K., Nakamura K. et al. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination. Oncotarget 2017;8(52):89887–902. DOI: 10.18632/oncotarget.20834Masuda T., Nakashima T., Namba M. et al. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med 2019;23(4):2984–94. DOI: 10.1111/jcmm.14205Xi X., Liu N., Wang Q. et al. ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death Dis 2019;10(10):757. DOI: 10.1038/s41419-019-1986-2Sunii M., Masuda T., Shimoji K. et al. Plasminogen activator inhibitor-1 mediates tolorance to anti-PD-1 immunotherapy in non-small cell lung cancer. Mol Cancer Ther 2025;25(3):435–47. DOI: 10.1158/1535-7163.MCT-24-0890Zaheer J., Shanmugiah J., Kim S. et al. Tumor microenvironment modulation by SERPINE1 increases radioimmunotherapy in murine model of gastric cancer. Sci Rep 2025;15(1):16449 DOI: 10.1038/s41598-025-97983-4Sillen M., Declerck P.J. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. Front Cardiovasc Med 2020;7:622473. DOI: 10.3389/fcvm.2020.622473Rahman F.A., Krause M.P. PAI-1, the plasminogen system, and skeletal muscle. Int J Mol Sci 2020;21(19):7066. DOI: 10.3390/ijms21197066